The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest venture, a biotechnology startup known as Mirador Therapeutics.

自身免疫药物开发公司普罗米修斯生物科学公司（Prometheus Biosciences）的高管们回来了，他们拥有超过4亿美元的资金来启动他们最新的风险投资，这是一家名为Mirador Therapeutics的生物技术初创公司。

Based in San Diego, Mirador looks similar to its predecessor, which Merck & Co. acquired roughly a year ago for nearly $11 billion. Like Prometheus, Mirador intends to develop drugs for inflammatory and fibrotic diseases. And like many biotech startups, the company intends to do so with a precision approach, using a combination of genetic insights, large datasets and tailored diagnostics to identify drug targets and patients who might be most likely to benefit from treatment..

总部位于圣地亚哥的米拉多（Mirador）与其前身相似，后者大约在一年前被默克公司（Merck&Co.）斥资近110亿美元收购。像普罗米修斯一样，米拉多打算开发治疗炎症和纤维化疾病的药物。与许多生物技术初创公司一样，该公司打算采用精确的方法，结合遗传见解、大型数据集和量身定制的诊断方法，确定最有可能从治疗中受益的药物靶标和患者。。

'The journey was unfinished,' said Mirador CEO Mark McKenna, Prometheus’ former leader, in an interview with BioPharma Dive.

普罗米修斯（Prometheus）前领导人米拉多（Mirador）首席执行官马克·麦肯纳（MarkMcKenna）在接受《生物制药潜水》（BiopharmaDive）采访时说，这段旅程还没有结束。

Prometheus’ work led to a drug aimed at a regulatory protein, TL1A, that’s implicated in inflammatory bowel disease. Its acquisition came amid a rush of dealmaking for new types of medicines for inflammatory conditions, which are typically treated with more blunt forces that tamp down the immune system.

普罗米修斯的工作导致了一种针对调节蛋白TL1A的药物，TL1A与炎症性肠病有关。它的收购正值一系列新型炎症性疾病药物的交易之际，这些药物通常会受到更猛烈的冲击，从而抑制免疫系统。

Following Prometheus’ buyout, Roche and Sanofi each bought into similar TL1A medicines from other developers..

在普罗米修斯收购之后，罗氏和赛诺菲分别从其他开发商那里购买了类似的TL1A药物。。

According to McKenna, though, Prometheus didn’t “finish the mission” it had originally taken on. So he brought many members of the team back together to try to build a company focused on precision therapies for autoimmune diseases, leaning on their experience and a wealth of data to develop new medicines for inflammatory conditions of the gut, lung and skin..

然而，据麦肯纳说，普罗米修斯并没有“完成最初承担的任务”。因此，他召集了团队的许多成员，试图建立一家专注于自身免疫性疾病精确治疗的公司，依靠他们的经验和丰富的数据来开发治疗肠道、肺部和皮肤炎症的新药。。

“It’s much broader than what we were doing before,” McKenna said.

麦肯纳说：“这比我们之前做的要广泛得多。”。

Mirador isn’t saying which conditions it’ll go after first, or which drug targets it’s identified. McKenna only revealed that those targets have “strong genetic ties” to the diseases it’s interested in. But he envisions advancing multiple new drug prospects over the next 18 months and also indicated the company, with its large bankroll, may do deals to bring in more advanced candidates as well..

米拉多并没有说它将首先治疗哪些疾病，也没有说它将针对哪些药物。麦肯纳只透露，这些目标与它感兴趣的疾病有“强烈的遗传联系”。但他设想在未来18个月内推进多种新药前景，并表示拥有巨额资金的公司也可能达成协议，引进更先进的候选人。。

“Speed is the new currency in biotech,” he said. “We demonstrated it before and we can do it again.”

“速度是生物技术的新货币，”他说。“我们之前已经演示过，我们可以再做一次。”

The company’s Series A round was led by Arch Venture Partners and includes a long list of investors such as OrbiMed, Fairmount, Fidelity Management and Sanofi. It is the largest private financing raised by a biotech startup so far in 2024, and one of the sector’s most sizable Series A rounds in recent years..

该公司的A轮融资由Arch Venture Partners牵头，包括OrbiMed、Fairmount、Fidelity Management和赛诺菲等众多投资者。这是2024年生物技术初创公司迄今为止筹集的最大规模的私人融资，也是近年来该行业规模最大的a轮融资之一。。

The financing comes at a time when private investment in biotech appears to be picking up after a multiyear slump. Industry insiders interviewed by BioPharma Dive earlier this year indicated that there’s been a recent surge in investments, particularly in newer companies. This week alone, three other biotech startups raised funding rounds of at least $150 million..

此次融资正值私人对生物技术的投资在经历了多年的低迷之后似乎正在回升之际。今年早些时候接受BioPharma Dive采访的业内人士表示，最近投资激增，尤其是对新公司的投资。仅在本周，其他三家生物技术初创公司就筹集了至少1.5亿美元的资金。。

A surge of investments has carried more advanced companies, too. In a recent report, analysts at the investment bank Jefferies wrote that public biotech stock fundings are on pace for their best quarter in three years. Initial public offerings are also on their fastest trajectory, in terms of total dollars raised, since 2021, according to BioPharma Dive data..

投资的激增也带来了更先进的公司。在最近的一份报告中，投资银行杰弗里斯（Jefferies）的分析师写道，公共生物技术股票基金正朝着三年来最好的季度发展。根据BioPharma Dive的数据，自2021年以来，首次公开募股（IPO）的筹资总额也处于最快的轨道上。。